The trajectory of companies tied to the drug's past presents a intricate investment landscape. While the initial success generated substantial profits , generic alternatives have significantly eroded revenue. Investing in connected pharmaceutical firms now requires a careful assessment of intellectual property protection , evolving healthcare ch… Read More